• Notifications
    This feature only available to registered users.
  • Alerts
    This feature only available to registered users
  • Welcome Guest!
  • Login Signup

Stock [ BUY ] / [ SELL ] Trading Strategies
. [ Show Details ]

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

LXRX [ Lexicon Pharmaceuticals Inc ]
Last Trade 6.2 Date 3/5/2021
Change % -6.91 % Price Change -0.46
Open 6.72 52 Week High 9.65
High 6.72 52 Week Low 1.03
Low 6.09 Type stock
Volume 402165 Average Volume 10184041
Prev Close 6.66 Stock Exchange NASDAQ
Bid 6.2 Ask 6.21
Bid Size 1 Ask Size 1
1st Yr Estimated EPS Growth 2nd Yr Estimated EPS Growth
2 Years Forward Earning Yield 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share Book Value Yield
Buy Back Yield CAPE Ratio
Cash Return Cash Flow per Share
Cash Flow Yield Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue EV / Pre Tax Income
EV / Revenue EV / Total Asset
Expected Dividend Growth Rate Free Cash Flow per Share
Free Caash Flow Ratio Free Cash Flow Yield
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio
PB Ratio PB Ratio 10 Year Growth
PB Ratio 3 Year Growth Cash Ratio 3 Year Average
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average PE Ratio 10 Year Growth
PE Ratio 10 Year High PE Ratio 10 Year Low
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg Price Change 1 Month
Price to Cash Ratio Price / EBITDA
Price to Sales Ratio Price to Sales Ratio 10 Year Growth
Price to Sales Ratio 3 Year Avg Price to Sales Ratio 5 Year Avg
Sale per Share Sales Yield
Sustainable Growth Rate Tangible Book Value per Share
Tangible Book Value per Share 3 year Avg Tangible Book Value per Share 5 year Avg
Total Asset per Share Total Yield
Working Capital per Share Working Capital per Share 3 Year Avg
Working Capital per Share 5 Year Avg Beta
Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company?s drug candidates include LX1031, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX4211 that has completed Phase II clinical trials to treat type 2 diabetes; LX2931, which is in Phase II clinical trials for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX1032 that has completed Phase II clinical trials to treat the symptoms associated with carcinoid syndrome. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. The company has drug discovery alliances with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. It also has drug development financing collaboration with Symphony Icon; collaboration agreement with Taconic Farms, Inc.; and an alliance with Nuevolution A/S, which provides access to Nuevolution?s Chemetics platform chemistry technology. The company was founded in 1995 and is headquartered in The Woodlands, Texas.